Stockreport

Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients w...

Summit Therapeutics Inc.  (SMMT) 
Last summit therapeutics inc. earnings: 6/12 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: summitplc.com/investors/investor-centre
PDF Summit Enters 2026 with Approximately $710 Million in Cash MIAMI, January 12, 2026 BUSINESS WIRE )--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "C [Read more]